New Delhi: At a time when the coronavirus is causing havoc in China and other countries, the Indian government has approved the use of the nasal vaccine as a booster dose in India. Bharat Biotech’s intranasal Covid vaccine has been approved by the Union Health Ministry as a booster dose. The vaccine will be used as a heterologous booster and will be first available in private hospitals for Rs 800 excluding GST.
Bharat Biotech’s intranasal vaccine, iNCOVACC, has been approved for people aged 18 and above. The vaccine can be administered as a precaution to adults who have taken 2 doses of either Covaxin or Covishield.
Bharat Biotech’s intranasal vaccine, iNCOVACC, is available at private hospitals and people can book appointments for nasal vaccines through the CoWIN platform. They also can book appointments for Covid nasal booster dose online via the CoWIN website and app from December 23, 2022.
Bharat Biotech’s intranasal vaccine iNCOVACC will cost Rs 800 each excluding 5 percent Goods and Services Tax (GST) in private hospitals. “The government of India has approved the nasal vaccine. It will be used as a heterologous booster and will be available first in private hospitals. It will be included in the Covid vaccination program,” the government said in a statement.
For breaking news and live news updates, like us on Facebook or follow us on Twitter and Instagram. Read more on Latest India News on India.com.
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts Cookies Policy.